Euglena Co., Ltd., Leave a Nest Co., Ltd., OMR Co., Ltd., produced a standard antibody against the new coronavirus (SARS-CoV-2) and confirmed the effect in the antibody test system under joint development.

Euglena Co., Ltd.
Leave a Nest Co., Ltd.
Made-to-order Medical Research Co., Ltd.

Euglena Co., Ltd. (President: Mitsuru Izumo), Revanes Co., Ltd. (Vice President and CTO: Jyo Inoue), and Custom-made Medical Research Co., Ltd. (President: Yasufumi Murakami) are jointly developing the new coronavirus SARS-^{A chimeric type * 2} anti-SARS that enables estimation of the concentration of anti-SARS-CoV-2 antibody contained in the blood of a subject in ^{an antibody test system * 1} related to CoV-2 (hereinafter, "SARS-CoV-2"). -We have succeeded in producing a CoV-2 antibody (hereinafter referred to as standard antibody).
* 1 The start of joint development was announced on June 15, 2020 https://www.euglena.jp/news/20200615-2/
* 2 An antibody that combines the variable part of a mouse antibody and the constant part of a human antibody.

3社で開発中のSARS-CoV-2に関する抗体検査系^※3では、被験者の血液中にSARS-CoV-2に対する抗体が存在するか否かを判定する定性的な検査はできましたが、SARS-CoV-2に結合する抗体の濃度を推定する定量的な検査はできませんでした。

In order to estimate the concentration of antibody contained in the blood of a subject, a comparative test using an antibody with a known concentration is required during the antibody test. ^{Therefore, we produced a monoclonal antibody *4} that reacts with the SARS-CoV-2 protein, and succeeded in obtaining a standard antibody with sufficient sensitivity. By using this antibody in the test, it is possible to estimate the concentration of anti-SARS-CoV-2 antibody as well as qualitative positive and negative judgment.
* 3 The results of the test for obtaining informed consent will be announced in the release dated July 6, 2020 https://www.euglena.jp/news/20200706-4/
* 4 A uniform antibody that reacts with a specific site of the antigen, and is used for the development of antibody tests for the purpose of diagnosis.

Using the standard antibody obtained this time, we evaluated the ^{blood sample * 5 that we had already tested for antibody.} As a result, we confirmed the validity of making a judgment based on the concentration of the standard antibody.
* 5 Antibodies provided by volunteers who have agreed to the antibody test system development test announced in the release dated June 15, 2020 (https://www.euglena.jp/news/20200615-2/). 203 blood samples tested

In the future, we will continue to develop a highly reliable antibody test system that is quantified using standard antibodies.

<About Euglena Co., Ltd.>
In 2005, we succeeded in establishing the world's first edible outdoor mass culture technology for the Euglena A company listed on the First Section of the Tokyo Stock Exchange that develops and sells functional foods and cosmetics that utilize the Euglena produced on Ishigaki Island, and conducts research and development for biofuel production. https://euglena.jp

<About Leave a Nest Co., Ltd.>
Based on the philosophy of "realizing the development of science and technology and contributing to the earth," we focus on science education, human resource development, research and development, and the creation of new businesses. Work on a typical project. https://lne.st/

<About Custom-made Medical Research Co., Ltd.>
Professor Yasufumi Murakami of Tokyo University of Science launched and established the LIMAXYS method, an innovative antibody production technology. An antibody drug venture that has made it possible to produce membrane protein antibodies, which was difficult to produce until now. https://www.omr.co.jp/

-Contact for inquiries from the press-
Euglena Co., Ltd. Corporate Communication Division